LLY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Eli Lilly (LLY) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and dominance in the obesity treatment market make it a solid choice despite minor pre-market price fluctuations and insider selling trends.
The MACD is negatively expanding (-3.986), indicating bearish momentum. RSI is neutral at 30.799, and moving averages are converging, showing no clear trend. The stock is near its S1 support level of 979.776, suggesting limited downside risk in the short term.
Strong Q4 financial performance with 42.56% YoY revenue growth and 50.52% YoY net income growth.
Launch of the Employer Connect platform to enhance access to obesity treatments, potentially expanding market reach.
Analysts maintain high price targets (up to $1,
and positive ratings, citing dominance in the obesity market and transformative catalysts.
Congress trading data shows balanced activity but includes significant purchase transactions, indicating confidence in the stock.
Insider selling has increased significantly (4519.16% over the last month), which may signal caution.
Technical indicators show bearish momentum in the short term.
Stock trend analysis suggests a potential short-term decline (-1.32% next day, -2.95% next week).
Eli Lilly delivered exceptional Q4 2025 results: Revenue increased by 42.56% YoY to $19.29B, net income grew by 50.52% YoY to $6.64B, and EPS rose by 51.43% YoY to 7.39. Gross margin improved slightly to 82.52%. These results underscore strong growth trends driven by the obesity treatment market.
Analysts are overwhelmingly positive on LLY, with multiple firms raising price targets (ranging from $1,200 to $1,350) and maintaining Buy/Outperform ratings. Analysts highlight the company's leadership in the obesity market and transformative catalysts such as the oral obesity drug launch and global market expansion.
